rAAV2.REP1 vector for choroideremia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 4 Mar 2014: Trial registered, NCT02077361
  2. 16 May 2022: Trial completed, NCT02077361

The trials

NCT02077361: An Open Label Clinical Trial of Retinal Gene Therapy for Choroideremia

State
Completed
Phase
Phase 1 and Phase 2
People
6 taking part
Started
Apr 2015
Primary completion
30 Aug 2017
Arms
Open Label
Results
None posted
  1. 4 Mar 2014: Trial registered
  2. 16 May 2022: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Gene therapy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.